51
|
Jingushi K, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Yamamoto Y, Hayashi T, Kinouchi T, Matsuzaki K, Kato T, Kawashima A, Ujike T, Nagahara A, Fujita K, Ueda K, Tsujikawa K, Nonomura N. Leukocyte‑associated immunoglobulin‑like receptor 1 promotes tumorigenesis in RCC. Oncol Rep 2018; 41:1293-1303. [PMID: 30483814 DOI: 10.3892/or.2018.6875] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Accepted: 11/12/2018] [Indexed: 11/06/2022] Open
Abstract
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90‑95% of cases. We previously reported a novel method that enables direct extraction of extracellular vesicles (EVs) from surgically resected viable tissues, yielding what we term tissue‑exudative extracellular vesicles (Te‑EVs). Quantitative LC/MS analysis identified 3,871 proteins in Te‑EVs, among which leukocyte‑associated immunoglobulin‑like receptor 1 (LAIR1) was highly enriched in tumor Te‑EVs. In the present study, we found that LAIR1 was significantly upregulated in clinical specimens of human RCC tumor tissues compared to that noted in adjacent non‑cancerous renal tissues as determined by quantitative PCR analysis. LAIR1 overexpression resulted in accelerated cell proliferation and tumor growth in RCC cells. Moreover, knockdown of LAIR1 using siRNA significantly inhibited cell proliferation in RCC cells. Mechanistically, LAIR1 upregulated the phosphorylation status of Akt, which in turn increased cell proliferation in RCC cells. In clinical RCC specimens, RCC patients with high LAIR1 mRNA expression showed poor progression‑free survival compared to those with low LAIR1 expression. These findings indicate that LAIR1 promotes tumorigenesis in RCC.
Collapse
|
52
|
Goda T, Kinoshita I, Oizumi S, Nakano K, Harada T, Kawai Y, Sakakibara-Konishi J, Yokouchi H, Morikawa N, Yamada N, Yamazaki S, Sugawara S, Asahina H, Amano T, Hatanaka Y, Matsuno Y, Nishihara H, Isobe H, Nishimura M, Dosaka-Akita H. A prospective observational study of HER2 alterations in NSCLCs: HOT1303-A. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
53
|
Oguri T, Nakano K, Fukuda N, Kawaguchi K, Urasaki T, Nishizawa M, Yunokawa M, Ono M, Taira S, Tomomatsu J, Toshiyasu T, Mitani H, Takahashi S. The retrospective analysis of nephrotoxicity for cisplatin dose of CRT compared 100 mg/m2 to 80 mg/m2 for head and neck cancer (HNC) patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
54
|
Fujiwara M, Matoba T, Koga J, Okahara A, Funamoto D, Nakano K, Tsutsui H, Egashira K. 2422Nanoparticle-mediated delivery of toll-like receptor 4 antagonist to monocytes and ischemic myocardium enhances cardioprotection against ischemia-reperfusion injury in mice. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.2422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
55
|
Okahara A, Matoba T, Koga J, Fujiwara M, Funamoto D, Nakano K, Tsutsui H, Egashira K. P1270Nanoparticle-mediated simultaneous targeting of mitochondria and inflammatory monocytes protects the brain from ischemia-reperfusion injury in mice. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
56
|
Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Yamamoto Y, Kinouchi T, Matsuzaki K, Jingushi K, Kato T, Kawashima A, Nagahara A, Ujike T, Uemura M, Pena MDCR, Gordetsky JB, Morii E, Tsujikawa K, Netto GJ, Nonomura N. High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling. Clin Cancer Res 2018; 24:4309-4318. [PMID: 29776955 DOI: 10.1158/1078-0432.ccr-18-0106] [Citation(s) in RCA: 107] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Revised: 04/19/2018] [Accepted: 05/14/2018] [Indexed: 01/22/2023]
Abstract
Purpose: High-fat diet (HFD) could induce prostate cancer progression. The aim of this study is to identify mechanisms of HFD-induced prostate cancer progression, focusing on inflammation.Experimental Design: We administered HFD and celecoxib to autochthonous immunocompetent Pb-Cre+;Pten(fl/fl) model mice for prostate cancer. Tumor growth was evaluated by tumor weight and Ki67 stain, and local immune cells were assessed by flow cytometry at 22 weeks of age. Cytokines which correlated with tumor growth were identified, and the changes of tumor growth and local immune cells after inhibition of the cytokine signals were evaluated in the mice. IHC analyses using prostatectomy specimens of obese patients were performed.Results: HFD accelerated tumor growth and increased the myeloid-derived suppressor cells (MDSCs) fraction and M2/M1 macrophage ratio in the model mice. Celecoxib-suppressed tumor growth, and decreased both local MDSCs and M2/M1 macrophage ratio in HFD-fed mice. HFD-induced tumor growth was associated with IL6 secreted by prostatic macrophages, as were phosphorylated STAT3 (pSTAT3)-positive tumor cells. Anti-IL6 receptor antibody administration suppressed tumor growth, and decreased local MDSCs and pSTAT3-positive cell fractions in HFD-fed mice. The tumor-infiltrating CD11b-positive cell count was significantly higher in prostatectomy specimens of obese than those of nonobese patients with prostate cancer.Conclusions: HFD increased MDSCs and accelerated prostate cancer tumor growth via IL6/pSTAT3 signaling in the mice. This mechanism could exist in obese patients with prostate cancer. IL6-mediated inflammation could be a therapeutic target for prostate cancer. Clin Cancer Res; 24(17); 4309-18. ©2018 AACR.
Collapse
|
57
|
Yamamoto Y, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Kinouchi T, Hayashi T, Matsuzaki K, Jingushi K, Kato T, Kawashima A, Ujike T, Nagahara A, Fujita K, Imamura R, Nonomura N. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. Oncotarget 2018; 9:20467-20475. [PMID: 29755665 PMCID: PMC5945531 DOI: 10.18632/oncotarget.24943] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 03/11/2018] [Indexed: 01/05/2023] Open
Abstract
Background Reliable biomarkers for renal cell carcinoma (RCC) have yet to be found. Circulating cell-free DNA (cfDNA) is an emerging resource for the diagnosis and prognosis of various cancers. This study aims to identify novel blood biomarkers for RCC. Materials And Methods Plasma cfDNA was extracted from RCC patients (n = 92) and healthy controls (n = 41). Levels of cfDNA were determined using quantitative real-time PCR of ACTB as the target gene, and cfDNA fragment size was measured using a microfluidics-based platform. Diagnostic potential was assessed using receiver operating characteristic (ROC) and logistic regression analysis, and prognostic potential was evaluated using log-rank test. Results Median levels of cfDNA from RCC patients were significantly higher than those from healthy controls (3803 vs 2242 copies/ml, p < 0.001). Median fragment sizes of cfDNA in RCC patients were shorter than those in healthy controls (170 vs 171 bp, p = 0.052). To evaluate level of cfDNA as a diagnostic tool for RCC, ROC curve analysis revealed a sensitivity of 63.0% and a specificity of 78.1%. Multivariate analysis indicated that age, gender and the level of cfDNA were significantly associated with the presence of RCC (p < 0.001, p = 0.013, p < 0.001, respectively). Additionally, shorter cfDNA fragment size was negatively associated with progression-free survival (p = 0.006). Conclusions Our study demonstrates the diagnostic and prognostic potential of plasma cfDNA as a biomarker for RCC.
Collapse
|
58
|
Yamamoto Y, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Matsuzaki K, Hayashi T, Kinouchi T, Jingushi K, Kato T, Kawashima A, Ujike T, Nagahara A, Fujita K, Imamura R, Nonomura N. MP88-04 THE CLINICAL UTILITY OF ABSOLUTE COPY NUMBER AND FRAGMENT SIZE OF PLASMA CIRCULATING CELL-FREE DNA AS NOVEL BIOMARKERS IN RENAL CELL CARCINOMA PATIENTS. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.2924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
59
|
Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 2018; 27:802-811. [DOI: 10.1177/0961203317749047] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
Objective We examined the efficacy and safety of rituximab in patients with refractory systemic lupus erythematosus (SLE). Methods The study enrolled 63 SLE patients who were treated with rituximab between 2002 and 2015. The participants underwent a battery of tests before treatment and at one year. Treatment ranged from two to four times at 500 or 1000 mg. Results Baseline characteristics were males:females = 6:57, age 33.9 years, and disease duration 87.2 months. The primary endpoint: The rate of major clinical response (MCR) was 60% while the partial clinical response (PCR) was 25%. Thirty of 36 (83%) patients with lupus nephritis (WHO II: 2, III: 5, IV: 22, V: 4, IV+V: 2, not assessed: 1) and 22 of 24 patients (92%) with neuropsychiatric SLE, who could be followed at one year, showed changes from BILAG A or B score to C or D score at one year. Multivariate analysis identified high anti-dsDNA antibody and shorter disease duration as significant determinants of MCR at one year. Repeat examination was conducted at five years. Primary failure was recorded in 8.8% and secondary failure in 32.4% (time to relapse: 24.4 months). Rituximab was well tolerated although 65 adverse events, mostly infections, were recorded within one year. Conclusion Rituximab is potentially efficacious for the treatment of patients with refractory SLE.
Collapse
|
60
|
Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus 2018. [PMID: 29523055 DOI: 10.1177/0961203318762598] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
It has been reported that T helper 17 cells are involved in the pathogenesis of systemic lupus erythematosus, but there is no report on interleukin-17-targeted therapy. We report a case of a 62-year-old female who presented with psoriasis vulgaris and refractory lupus nephritis. Because her conditions were resistant to conventional treatment, and flow cytometry confirmed the proliferation of activated T helper 17 cells in peripheral blood, and examination of a renal biopsy tissue sample confirmed infiltration of numerous interleukin-17-positive lymphocytes to the renal interstitium, administration of the anti-interleukin-17A antibody secukinumab was initiated. After starting secukinumab the clinical and biological features were improved.
Collapse
|
61
|
Aidala C, Akiba Y, Alfred M, Andrieux V, Aoki K, Apadula N, Asano H, Ayuso C, Azmoun B, Babintsev V, Bagoly A, Bandara NS, Barish KN, Bathe S, Bazilevsky A, Beaumier M, Belmont R, Berdnikov A, Berdnikov Y, Blau DS, Boer M, Bok JS, Brooks ML, Bryslawskyj J, Bumazhnov V, Butler C, Campbell S, Canoa Roman V, Cervantes R, Chi CY, Chiu M, Choi IJ, Choi JB, Citron Z, Connors M, Cronin N, Csanád M, Csörgő T, Danley TW, Daugherity MS, David G, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond EJ, Dion A, Dixit D, Do JH, Drees A, Drees KA, Dumancic M, Durham JM, Durum A, Elder T, Enokizono A, En'yo H, Esumi S, Fadem B, Fan W, Feege N, Fields DE, Finger M, Finger M, Fokin SL, Frantz JE, Franz A, Frawley AD, Fukuda Y, Gal C, Gallus P, Garg P, Ge H, Giordano F, Goto Y, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guragain H, Hachiya T, Haggerty JS, Hahn KI, Hamagaki H, Hamilton HF, Han SY, Hanks J, Hasegawa S, Haseler TOS, He X, Hemmick TK, Hill JC, Hill K, Hodges A, Hollis RS, Homma K, Hong B, Hoshino T, Hotvedt N, Huang J, Huang S, Imai K, Imrek J, Inaba M, Iordanova A, Isenhower D, Ito Y, Ivanishchev D, Jacak BV, Jezghani M, Ji Z, Jiang X, Johnson BM, Jorjadze V, Jouan D, Jumper DS, Kang JH, Kapukchyan D, Karthas S, Kawall D, Kazantsev AV, Khachatryan V, Khanzadeev A, Kim C, Kim DJ, Kim EJ, Kim M, Kim MH, Kincses D, Kistenev E, Klatsky J, Kline P, Koblesky T, Kotov D, Kudo S, Kurita K, Kwon Y, Lajoie JG, Lallow EO, Lebedev A, Lee S, Lee SH, Leitch MJ, Leung YH, Lewis NA, Li X, Lim SH, Liu LD, Liu MX, Loggins VR, Lökös S, Lovasz K, Lynch D, Majoros T, Makdisi YI, Makek M, Malaev M, Manko VI, Mannel E, Masuda H, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Mendoza M, Metzger WJ, Mignerey AC, Mihalik DE, Milov A, Mishra DK, Mitchell JT, Mitsuka G, Miyasaka S, Mizuno S, Montuenga P, Moon T, Morrison DP, Morrow SIM, Murakami T, Murata J, Nagai K, Nagashima K, Nagashima T, Nagle JL, Nagy MI, Nakagawa I, Nakagomi H, Nakano K, Nattrass C, Niida T, Nouicer R, Novák T, Novitzky N, Novotny R, Nyanin AS, O'Brien E, Ogilvie CA, Orjuela Koop JD, Osborn JD, Oskarsson A, Ottino GJ, Ozawa K, Pantuev V, Papavassiliou V, Park JS, Park S, Pate SF, Patel M, Peng W, Perepelitsa DV, Perera GDN, Peressounko DY, PerezLara CE, Perry J, Petti R, Phipps M, Pinkenburg C, Pisani RP, Pun A, Purschke ML, Radzevich PV, Read KF, Reynolds D, Riabov V, Riabov Y, Richford D, Rinn T, Rolnick SD, Rosati M, Rowan Z, Runchey J, Safonov AS, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato K, Sato S, Schaefer B, Schmoll BK, Sedgwick K, Seidl R, Sen A, Seto R, Sexton A, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shioya T, Shukla P, Sickles A, Silva CL, Silvermyr D, Singh BK, Singh CP, Singh V, Skoby MJ, Slunečka M, Smith KL, Snowball M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stoll SP, Sugitate T, Sukhanov A, Sumita T, Sun J, Syed S, Sziklai J, Takeda A, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarnai G, Tieulent R, Timilsina A, Todoroki T, Tomášek M, Towell CL, Towell RS, Tserruya I, Ueda Y, Ujvari B, van Hecke HW, Vazquez-Carson S, Velkovska J, Virius M, Vrba V, Vukman N, Wang XR, Wang Z, Watanabe Y, Watanabe YS, Wong CP, Woody CL, Xu C, Xu Q, Xue L, Yalcin S, Yamaguchi YL, Yamamoto H, Yanovich A, Yin P, Yoo JH, Yoon I, Yu H, Yushmanov IE, Zajc WA, Zelenski A, Zharko S, Zou L. Measurements of Multiparticle Correlations in d+Au Collisions at 200, 62.4, 39, and 19.6 GeV and p+Au Collisions at 200 GeV and Implications for Collective Behavior. PHYSICAL REVIEW LETTERS 2018; 120:062302. [PMID: 29481251 DOI: 10.1103/physrevlett.120.062302] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Indexed: 06/08/2023]
Abstract
Recently, multiparticle-correlation measurements of relativistic p/d/^{3}He+Au, p+Pb, and even p+p collisions show surprising collective signatures. Here, we present beam-energy-scan measurements of two-, four-, and six-particle angular correlations in d+Au collisions at sqrt[s_{NN}]=200, 62.4, 39, and 19.6 GeV. We also present measurements of two- and four-particle angular correlations in p+Au collisions at sqrt[s_{NN}]=200 GeV. We find the four-particle cumulant to be real valued for d+Au collisions at all four energies. We also find that the four-particle cumulant in p+Au has the opposite sign as that in d+Au. Further, we find that the six-particle cumulant agrees with the four-particle cumulant in d+Au collisions at 200 GeV, indicating that nonflow effects are subdominant. These observations provide strong evidence that the correlations originate from the initial geometric configuration, which is then translated into the momentum distribution for all particles, commonly referred to as collectivity.
Collapse
|
62
|
Aidala C, Akiba Y, Alfred M, Andrieux V, Aoki K, Apadula N, Asano H, Ayuso C, Azmoun B, Babintsev V, Bagoly A, Bandara NS, Barish KN, Bathe S, Bazilevsky A, Beaumier M, Belmont R, Berdnikov A, Berdnikov Y, Blau DS, Boer M, Bok JS, Brooks ML, Bryslawskyj J, Bumazhnov V, Butler C, Campbell S, Canoa Roman V, Cervantes R, Chi CY, Chiu M, Choi IJ, Choi JB, Citron Z, Connors M, Cronin N, Csanád M, Csörgő T, Danley TW, Daugherity MS, David G, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond EJ, Dion A, Dixit D, Do JH, Drees A, Drees KA, Dumancic M, Durham JM, Durum A, Elder T, Enokizono A, En'yo H, Esumi S, Fadem B, Fan W, Feege N, Fields DE, Finger M, Finger M, Fokin SL, Frantz JE, Franz A, Frawley AD, Fukuda Y, Gal C, Gallus P, Garg P, Ge H, Giordano F, Goto Y, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guragain H, Hachiya T, Haggerty JS, Hahn KI, Hamagaki H, Hamilton HF, Han SY, Hanks J, Hasegawa S, Haseler TOS, He X, Hemmick TK, Hill JC, Hill K, Hollis RS, Homma K, Hong B, Hoshino T, Hotvedt N, Huang J, Huang S, Imai K, Imrek J, Inaba M, Iordanova A, Isenhower D, Ito Y, Ivanishchev D, Jacak BV, Jezghani M, Ji Z, Jiang X, Johnson BM, Jorjadze V, Jouan D, Jumper DS, Kang JH, Kapukchyan D, Karthas S, Kawall D, Kazantsev AV, Khachatryan V, Khanzadeev A, Kim C, Kim DJ, Kim EJ, Kim M, Kim MH, Kincses D, Kistenev E, Klatsky J, Kline P, Koblesky T, Kotov D, Kudo S, Kurita K, Kwon Y, Lajoie JG, Lallow EO, Lebedev A, Lee S, Leitch MJ, Leung YH, Lewis NA, Li X, Lim SH, Liu LD, Liu MX, Loggins VR, Lökös S, Lovasz K, Lynch D, Majoros T, Makdisi YI, Makek M, Malaev M, Manko VI, Mannel E, Masuda H, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Mendoza M, Metzger WJ, Mignerey AC, Mihalik DE, Milov A, Mishra DK, Mitchell JT, Mitsuka G, Miyasaka S, Mizuno S, Montuenga P, Moon T, Morrison DP, Morrow SIM, Murakami T, Murata J, Nagai K, Nagashima K, Nagashima T, Nagle JL, Nagy MI, Nakagawa I, Nakagomi H, Nakano K, Nattrass C, Niida T, Nouicer R, Novák T, Novitzky N, Novotny R, Nyanin AS, O'Brien E, Ogilvie CA, Orjuela Koop JD, Osborn JD, Oskarsson A, Ottino GJ, Ozawa K, Pantuev V, Papavassiliou V, Park JS, Park S, Pate SF, Patel M, Peng W, Perepelitsa DV, Perera GDN, Peressounko DY, PerezLara CE, Perry J, Petti R, Phipps M, Pinkenburg C, Pisani RP, Pun A, Purschke ML, Radzevich PV, Read KF, Reynolds D, Riabov V, Riabov Y, Richford D, Rinn T, Rolnick SD, Rosati M, Rowan Z, Runchey J, Safonov AS, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato K, Sato S, Schaefer B, Schmoll BK, Sedgwick K, Seidl R, Sen A, Seto R, Sexton A, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shioya T, Shukla P, Sickles A, Silva CL, Silvermyr D, Singh BK, Singh CP, Singh V, Skoby MJ, Slunečka M, Smith KL, Snowball M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stoll SP, Sugitate T, Sukhanov A, Sumita T, Sun J, Syed S, Sziklai J, Takeda A, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarnai G, Tieulent R, Timilsina A, Todoroki T, Tomášek M, Towell CL, Towell RS, Tserruya I, Ueda Y, Ujvari B, van Hecke HW, Vazquez-Carson S, Velkovska J, Virius M, Vrba V, Vukman N, Wang XR, Wang Z, Watanabe Y, Watanabe YS, Wong CP, Woody CL, Xu C, Xu Q, Xue L, Yalcin S, Yamaguchi YL, Yamamoto H, Yanovich A, Yin P, Yoo JH, Yoon I, Yu H, Yushmanov IE, Zajc WA, Zelenski A, Zharko S, Zou L. Nuclear Dependence of the Transverse-Single-Spin Asymmetry for Forward Neutron Production in Polarized p+A Collisions at sqrt[s_{NN}]=200 GeV. PHYSICAL REVIEW LETTERS 2018; 120:022001. [PMID: 29376675 DOI: 10.1103/physrevlett.120.022001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Revised: 09/26/2017] [Indexed: 06/07/2023]
Abstract
During 2015, the Relativistic Heavy Ion Collider (RHIC) provided collisions of transversely polarized protons with Au and Al nuclei for the first time, enabling the exploration of transverse-single-spin asymmetries with heavy nuclei. Large single-spin asymmetries in very forward neutron production have been previously observed in transversely polarized p+p collisions at RHIC, and the existing theoretical framework that was successful in describing the single-spin asymmetry in p+p collisions predicts only a moderate atomic-mass-number (A) dependence. In contrast, the asymmetries observed at RHIC in p+A collisions showed a surprisingly strong A dependence in inclusive forward neutron production. The observed asymmetry in p+Al collisions is much smaller, while the asymmetry in p+Au collisions is a factor of 3 larger in absolute value and of opposite sign. The interplay of different neutron production mechanisms is discussed as a possible explanation of the observed A dependence.
Collapse
|
63
|
Uematsu K, Noguchi K, Nakano K. Synthesis and properties of [7]helicene and [7]helicene-like compounds with a cyclopenta[1,2-b:4,3-b′]dithiophene or dithieno[2,3-b:3′,2′-d]heterole skeleton. Phys Chem Chem Phys 2018; 20:3286-3295. [DOI: 10.1039/c7cp06342c] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of [7]helicene and [7]helicene-like compounds composed of a cyclopenta[1,2-b:4,3-b′]dithiophene or dithieno[2,3-b:3′,2′-d]heterole moiety and two naphthalene moieties were successfully synthesized from a common synthetic intermediate, 1,1′-binaphtho[2,1-b]thiophene.
Collapse
|
64
|
Hirose K, Nishio K, Tanaka S, Léguillon R, Makii H, Nishinaka I, Orlandi R, Tsukada K, Smallcombe J, Vermeulen MJ, Chiba S, Aritomo Y, Ohtsuki T, Nakano K, Araki S, Watanabe Y, Tatsuzawa R, Takaki N, Tamura N, Goto S, Tsekhanovich I, Andreyev AN. Role of Multichance Fission in the Description of Fission-Fragment Mass Distributions at High Energies. PHYSICAL REVIEW LETTERS 2017; 119:222501. [PMID: 29286806 DOI: 10.1103/physrevlett.119.222501] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Indexed: 06/07/2023]
Abstract
Fission-fragment mass distributions were measured for ^{237-240}U, ^{239-242}Np, and ^{241-244}Pu populated in the excitation-energy range from 10 to 60 MeV by multinucleon transfer channels in the reaction ^{18}O+^{238}U at the Japan Atomic Energy Agency tandem facility. Among them, the data for ^{240}U and ^{240,241,242}Np were observed for the first time. It was found that the mass distributions for all the studied nuclides maintain a double-humped shape up to the highest measured energy in contrast to expectations of predominantly symmetric fission due to the washing out of nuclear shell effects. From a comparison with the dynamical calculation based on the fluctuation-dissipation model, this behavior of the mass distributions was unambiguously attributed to the effect of multichance fission.
Collapse
|
65
|
Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Yamamoto Y, Kinouchi T, Matsuzaki K, Kawamura N, Jingushi K, Kawashima A, Nagahara A, Ujike T, Uemura M, Imamura R, Morii E, Nonomura N. Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens. Prostate 2017; 77:1383-1388. [PMID: 28845570 DOI: 10.1002/pros.23398] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2017] [Accepted: 07/11/2017] [Indexed: 01/10/2023]
Abstract
BACKGROUND Tumor-infiltrating macrophages, which are thought to be derived from blood monocytes, interact with tumor cells to promote cancer progression. The aim of this study was to assess the association of peripheral blood monocyte count with pathological findings and local tumor-infiltrating macrophages in prostatectomy specimens. METHODS Preoperative peripheral blood monocyte counts were retrospectively assessed for their associations with pathological findings (pathological T stage, Gleason Score, extraprostatic extension, seminal vesicle invasion, and surgical margin) and biochemical recurrence of 248 patients who underwent radical prostatectomy. Local tumor-infiltrating macrophages were also evaluated immunohistochemically for their association with peripheral monocyte counts. RESULTS The peripheral monocyte counts of the patients with extraprostatic extension, seminal vesicle invasion, or primary Gleason ≥4 were significantly higher than those of the patients without each of these pathological findings (P < 0.001, P = 0.034, and P = 0.004, respectively). Peripheral monocyte count was a significant predictor of adverse pathology and postoperative biochemical recurrence in localized prostate cancer by multivariate analysis (P = 0.001 and P = 0.041, respectively). Both the density and the count of tumor-infiltrating macrophages correlated significantly with the peripheral blood monocyte count (Spearman rank correlation coefficients were 0.463 and 0.649, respectively, P < 0.001). CONCLUSIONS Peripheral blood monocyte count reflecting local tumor-infiltrating macrophages was a predictive factor for tumor progression and prognosis in patients with localized prostate cancer. Elucidating the mechanism of the interaction of peripheral monocytes with tumor-infiltrating macrophages is necessary.
Collapse
|
66
|
Tomomatsu J, Iwasa S, Saka H, Takahashi S, Nakano K, Morita S, Inoue M, Nakahama H, Kogure Y, Kakizume T, Natsume K, Aoki T, Quadt C, Yamada Y, Ando Y. A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
67
|
Nariyoshi S, Sho T, Nakano K, Yamamoto K, Sukegawa G, Tsuji Y. Clinical value of ultrasonographic (US) analysis of seminiferous tubules for predicting successful sperm retrieval in patients with non-obstructive azoospermia (NOA). Fertil Steril 2017. [DOI: 10.1016/j.fertnstert.2017.07.905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
68
|
Iiya M, Shimizu M, Taomoto Y, Amemiya M, Sato Y, Yamakami Y, Nakamura R, Nakano K, Shimada H, Fujii H, Yamawake N, Nishizaki M. P6431Impact of hemoglobin level for prediction of neurological-full-recovery in patients with out-of-hospital-cardiac-arrest after return-of-spontaneous-circulation. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
69
|
Honda K, Matoba T, Koga J, Nakano K, Tsutsui H, Egashira K. P698High cholesterol diet and angiotensin II induce spontaneous atherothrombotic occlusion of balloon-injured rabbit femoral arteries; effects of lipid-lowering therapies. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
70
|
Sato Y, Shimizu M, Taomoto Y, Amemiya M, Iiya M, Yamakami Y, Nakamura R, Nakano K, Shimada H, Fujii H, Yamawake N, Nishizaki M, Sakurada H, Hiraoka M. P6427The prognostic value of high-frequency component in holter electrocardiograms on lethal arrhythmia in patients with vasospastic angina. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
71
|
Shimizu M, Taomoto Y, Amemiya M, Yamakami Y, Sato Y, Iiya M, Nakamura R, Nakano K, Shimada H, Fujii H, Yamawake N, Nishizaki M, Sakurada H, Hiraoka M. P881Diagnostic performance of T-axis deviation on 12-leads electrocardiography for myocardial ischemia: Analysis by semiconductor SPECT. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
72
|
Shimizu M, Taomoto Y, Amemiya M, Yamakami Y, Sato Y, Iiya M, Nakamura R, Nakano K, Shimada H, Fujii H, Yamawake N, Nishizaki M, Sakurada H, Hiraoka M. P1458Prognostic value of T wave axis deviation for left ventricular dysfunction in patients with complete left bundle branch block. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
73
|
Aidala C, Ajitanand N, Akiba Y, Akimoto R, Alexander J, Alfred M, Aoki K, Apadula N, Asano H, Atomssa E, Awes T, Ayuso C, Azmoun B, Babintsev V, Bagoly A, Bai M, Bai X, Bannier B, Barish K, Bathe S, Baublis V, Baumann C, Baumgart S, Bazilevsky A, Beaumier M, Belmont R, Berdnikov A, Berdnikov Y, Black D, Blau D, Boer M, Bok J, Boyle K, Brooks M, Bryslawskyj J, Buesching H, Bumazhnov V, Butler C, Butsyk S, Campbell S, Canoa Roman V, Chen CH, Chi C, Chiu M, Choi I, Choi J, Choi S, Christiansen P, Chujo T, Cianciolo V, Cole B, Connors M, Cronin N, Crossette N, Csanád M, Csörgő T, Danley T, Datta A, Daugherity M, David G, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond E, Ding L, Do J, D’Orazio L, Drapier O, Drees A, Drees K, Dumancic M, Durham J, Durum A, Elder T, Engelmore T, Enokizono A, Esumi S, Eyser K, Fadem B, Fan W, Feege N, Fields D, Finger M, Finger M, Fleuret F, Fokin S, Frantz J, Franz A, Frawley A, Fukao Y, Fukuda Y, Fusayasu T, Gainey K, Gal C, Garg P, Garishvili A, Garishvili I, Ge H, Giordano F, Glenn A, Gong X, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene S, Grosse Perdekamp M, Gu Y, Gunji T, Guragain H, Hachiya T, Haggerty J, Hahn K, Hamagaki H, Han S, Hanks J, Hasegawa S, Haseler T, Hashimoto K, Hayano R, He X, Hemmick T, Hester T, Hill J, Hill K, Hollis R, Homma K, Hong B, Hoshino T, Hotvedt N, Huang J, Huang S, Ichihara T, Ikeda Y, Imai K, Imazu Y, Imrek J, Inaba M, Iordanova A, Isenhower D, Isinhue A, Ito Y, Ivanishchev D, Jacak B, Jeon S, Jezghani M, Ji Z, Jia J, Jiang X, Johnson B, Joo K, Jorjadze V, Jouan D, Jumper D, Kamin J, Kanda S, Kang B, Kang J, Kang J, Kapukchyan D, Kapustinsky J, Karthas S, Kawall D, Kazantsev A, Key J, Khachatryan V, Khandai P, Khanzadeev A, Kijima K, Kim C, Kim D, Kim EJ, Kim M, Kim M, Kim YJ, Kim Y, Kincses D, Kistenev E, Klatsky J, Kleinjan D, Kline P, Koblesky T, Kofarago M, Komkov B, Koster J, Kotchetkov D, Kotov D, Krizek F, Kudo S, Kurita K, Kurosawa M, Kwon Y, Lacey R, Lai Y, Lajoie J, Lallow E, Lebedev A, Lee D, Lee G, Lee J, Lee K, Lee K, Lee S, Leitch M, Leitgab M, Leung Y, Lewis B, Lewis N, Li X, Li X, Lim S, Liu L, Liu M, Loggins VR, Lokos S, Lynch D, Maguire C, Majoros T, Makdisi Y, Makek M, Malaev M, Manion A, Manko V, Mannel E, Masuda H, McCumber M, McGaughey P, McGlinchey D, McKinney C, Meles A, Mendoza M, Meredith B, Metzger W, Miake Y, Mibe T, Mignerey A, Mihalik D, Milov A, Mishra D, Mitchell J, Mitsuka G, Miyasaka S, Mizuno S, Mohanty A, Mohapatra S, Moon T, Morrison D, Morrow S, Moskowitz M, Moukhanova T, Murakami T, Murata J, Mwai A, Nagae T, Nagai K, Nagamiya S, Nagashima K, Nagashima T, Nagle J, Nagy M, Nakagawa I, Nakagomi H, Nakamiya Y, Nakamura K, Nakamura T, Nakano K, Nattrass C, Netrakanti P, Nihashi M, Niida T, Nouicer R, Novák T, Novitzky N, Novotny R, Nyanin A, O’Brien E, Ogilvie C, Oide H, Okada K, Orjuela Koop J, Osborn J, Oskarsson A, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park I, Park J, Park S, Park S, Pate S, Patel L, Patel M, Peng JC, Peng W, Perepelitsa D, Perera G, Peressounko D, PerezLara C, Perry J, Petti R, Phipps M, Pinkenburg C, Pisani R, Pun A, Purschke M, Qu H, Radzevich P, Rak J, Ravinovich I, Read K, Reynolds D, Riabov V, Riabov Y, Richardson E, Richford D, Rinn T, Riveli N, Roach D, Rolnick S, Rosati M, Rowan Z, Runchey J, Ryu M, Sahlmueller B, Saito N, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato K, Sato S, Sawada S, Schaefer B, Schmoll B, Sedgwick K, Seele J, Seidl R, Sekiguchi Y, Sen A, Seto R, Sett P, Sexton A, Sharma D, Shaver A, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva C, Silvermyr D, Singh B, Singh C, Singh V, Skoby M, Skolnik M, Slunečka M, Smith K, Solano S, Soltz R, Sondheim W, Sorensen S, Sourikova I, Stankus P, Steinberg P, Stenlund E, Stepanov M, Ster A, Stoll S, Stone M, Sugitate T, Sukhanov A, Sun J, Syed S, Takahara A, Takeda A, Taketani A, Tanaka Y, Tanida K, Tannenbaum M, Tarafdar S, Taranenko A, Tarnai G, Tennant E, Tieulent R, Timilsina A, Todoroki T, Tomášek M, Torii H, Towell C, Towell R, Tserruya I, Ueda Y, Ujvari B, van Hecke H, Vargyas M, Vazquez-Carson S, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vrba V, Vznuzdaev E, Wang X, Wang Z, Watanabe D, Watanabe K, Watanabe Y, Watanabe Y, Wei F, Whitaker S, Wolin S, Wong C, Woody C, Wysocki M, Xia B, Xu C, Xu Q, Yamaguchi Y, Yanovich A, Yin P, Yokkaichi S, Yoo J, Yoon I, You Z, Younus I, Yu H, Yushmanov I, Zajc W, Zelenski A, Zharko S, Zhou S, Zou L. Cross section and transverse single-spin asymmetry of muons from open heavy-flavor decays in polarized
p+p
collisions at
s=200 GeV. Int J Clin Exp Med 2017. [DOI: 10.1103/physrevd.95.112001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
74
|
Akioka K, Ishikawa T, Osaka M, Kadotani Y, Okugawa K, Nakano K, Osaka Y, Tsuchiya K, Sako H. Hyperuricemia and Acute Renal Failure in Renal Transplant Recipients Treated With High-Dose Mizoribine. Transplant Proc 2017; 49:73-77. [PMID: 28104163 DOI: 10.1016/j.transproceed.2016.11.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Hyperuricemia is a common adverse event frequently found in renal transplant recipients with mizoribine (MZ). Hyperuricemia itself will be a cause of renal dysfunction, and renal dysfunction also will be a cause of hyperuricemia simultaneously. This study investigates frequency of hyperuricemia and renal failure in renal transplant recipients treated with high-dose MZ. PATIENTS AND METHODS From December 2007 to October 2015, there was a total of 32 living related renal transplant recipients treated with high-dose MZ. Of the 32 patients, 28 were treated with urate-lowering medications. RESULTS One patient received allopurinol (AP) and 13 patients received benzbromarone (BB). For 6 of them, their urate-lowering medications were converted to febuxostat (FX) form AP or BB. In the remaining 14 patients, FX was administered from the beginning. In 2 cases of ABO-incompatible living related renal transplant recipients who were maintained with high-dose MZ and BB, severe hyperuricemia and acute renal failure occurred. One patient was a 48-year-old man, and his creatinine (Cr) level increased to 8.14 mg/dL and his serum uric acid (UA) was 24.6 mg/dL. Another patient was a 57-year-old man, and his Cr level increased to 3.59 mg/dL and his UA was 13.2 mg/dL. In both cases Cr and UA were improved, and no finding of acute rejection and drug toxicity was observed in graft biopsy specimens. BB was switched to FX and discontinuance or reduction of MZ was done. CONCLUSION Combination of MZ and BB has the risk of acute renal dysfunction after renal transplantation. Latent renal dysfunction should be watched for in renal transplant recipients receiving high-dose MZ.
Collapse
|
75
|
Kuribayashi S, Takao T, Okuda Y, Kawamura M, Nakano K, Kishimoto N, Takezawa K, Tanigawa G, Tsutahara K, Watanabe H, Umayahara Y, Yamaguchi S. Case of pazopanib-induced thyrotoxicosis in a patient with metastatic renal cell carcinoma. Int Cancer Conf J 2017; 6:118-120. [PMID: 31149484 DOI: 10.1007/s13691-017-0288-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2017] [Accepted: 03/22/2017] [Indexed: 11/24/2022] Open
Abstract
Pazopanib is an oral multi-targeted tyrosine kinase inhibitor and has been approved for metastatic renal cell carcinoma and advanced soft tissue sarcoma. To the best of our knowledge, pazopanib-induced thyrotoxicosis has never been reported. The patient was a 68-year-old woman with renal cell carcinoma and multiple metastases. Three weeks after pazopanib medication, she felt fatigue and palpitation. She was admitted because of liver chemistry abnormalities [AST 723 IU/L (normal range 7-37 IU/L); ALT 953 IU/L (normal range 3-33 IU/L)]. She showed abnormal thyroid function tests with suppressed TSH of 0.0585 μIU/mL, and elevated fT4 of 3.38 ng/dL. Ten days after admission, tachycardia appeared and fT3 and fT4 were elevated (fT3 27.85 pg/mL, fT4 2.58 ng/dL), and TSH was suppressed (0.0414 μIU/mL). Her thyroid ultrasound showed hypervascular thyroid gland without nodules. We diagnosed pazopanib-induced thyrotoxicosis. Because the fT3/fT4 ratio was high (10.8) and the thyroid was enlarged, we thought that her thyrotoxicosis might get worse. She was treated with medication of beta-blockers, hydrocortisone, and potassium iodide and thyrotoxicosis resolved. This report highlights that Pazopanib could induce thyrotoxicosis, and therefore, periodic surveillance of thyroid function is required during pazopanib therapy.
Collapse
|